Drug class
Diterpene ester; topical cytotoxic agent for actinic keratosis (withdrawn in EU)
Mechanism of action
Induces rapid cell death and inflammatory responses in treated epidermal cells. The precise molecular pathways are not fully defined; post-marketing evidence raised concerns about increased risk of skin malignancies.
General use cases
- Historical topical indication: treatment of actinic keratosis in adults. The EU marketing authorisation for Picato was withdrawn in 2020 following concerns about skin malignancy risk; it should not be presented as a currently authorised EU treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
